Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jiangsu Aidea Pharmaceutical Group Co (SHSE:688488) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Jiangsu Aidea Pharmaceutical Group Co EBITDA Margin % Related Terms
Jiangsu Aidea Pharmaceutical Group Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Aidea Pharmaceutical Group Co EBITDA Margin % Chart
SHSE:688488 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Jiangsu Aidea Pharmaceutical Group Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Aidea Pharmaceutical Group Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jiangsu Aidea Pharmaceutical Group Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Jiangsu Aidea Pharmaceutical Group Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Aidea Pharmaceutical Group Co (SHSE:688488) has a EBITDA Margin % of 11.26% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jiangsu Aidea Pharmaceutical Group Co and its competitors. This is 277% above median its historical median of 2.99. According to the industry distribution chart, Jiangsu Aidea Pharmaceutical Group Co ranks #288 out of 939 companies in the Biotechnology industry, placing it in the top 30.7%.
Is Jiangsu Aidea Pharmaceutical Group Co's EBITDA Margin % too high?
Jiangsu Aidea Pharmaceutical Group Co's current EBITDA Margin % of 11.26% is 277% above median its 10-year median of 2.99. Based on the distribution chart, Jiangsu Aidea Pharmaceutical Group Co ranks #288 out of 939 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Jiangsu Aidea Pharmaceutical Group Co has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Aidea Pharmaceutical Group Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jiangsu Aidea Pharmaceutical Group Co ranks #288 out of 939 companies for EBITDA Margin %. This puts Jiangsu Aidea Pharmaceutical Group Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jiangsu Aidea Pharmaceutical Group Co and its competitors. Jiangsu Aidea Pharmaceutical Group Co's current EBITDA Margin % is 11.26%, which is 277% above median its own 10-year median of 2.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Aidea Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Aidea Pharmaceutical Group Co (SHSE:688488) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥23.63, compared to a current price of ¥15.72 — trading 33.5% below its estimated fair value. The current EBITDA Margin % is 11.26%, which is 277% above median its 10-year median of 2.99. Jiangsu Aidea Pharmaceutical Group Co's overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Jiangsu Aidea Pharmaceutical Group Co (SHSE:688488), the current EBITDA Margin % is 11.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Aidea Pharmaceutical Group Co (SHSE:688488) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Aidea Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of ¥15.72 is trading 33.5% below its estimated GF Value™ of ¥23.63.
GuruFocus considers Jiangsu Aidea Pharmaceutical Group Co to be Significantly Undervalued.
Key valuation signals for SHSE:688488:
EBITDA Margin %: 11.26% (277% above median its 10-year median of 2.99)
GF Value™: ¥23.63 vs. price of ¥15.72 (33.5% below fair value)
No single metric tells the full story. See the SHSE:688488 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Aidea Pharmaceutical Group Co Business Description
Jiangsu Aidea Pharmaceutical Group Co Ltd is engaged in the production and sales of human protein products, and also carries out some generic drug business and distributes Abbott's HIV diagnostic equipment and reagents.
67GF Score
Get the complete analysis for SHSE:688488
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688488 has been successfully added to your 
